Vitamin D and vascular disease: The current and future status of vitamin D therapy in hypertension and kidney disease

Current Hypertension Reports

Volumn 14, Issue 2, 2012, Pages 111-119

  Vaidya, Anand ^a   Forman, John P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

25 OH D; Blood pressure; Clinical trials; Hypertension; Kidney disease; Paricalcitol; Renin angiotensin system; Renoprotection; Vascular disease; Vitamin D

Indexed keywords

ALBUMIN; CALCITRIOL; CALCITRIOL DERIVATIVE; COLECALCIFEROL; ERGOCALCIFEROL; PARICALCITOL; PLACEBO; VITAMIN D;

ALBUMINURIA; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DRUG ACTIVITY; ENDOTHELIUM; FOLLOW UP; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; NONHUMAN; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT DURATION; URINARY EXCRETION; VASCULAR DISEASE; VITAMIN SUPPLEMENTATION;

ANTIHYPERTENSIVE AGENTS; BONE DENSITY CONSERVATION AGENTS; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; KIDNEY DISEASES; RENIN-ANGIOTENSIN SYSTEM; VITAMIN D;

EID: 84861101473     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-012-0248-9     Document Type: Review

References (94)

1. Holick MF. Viatamin D deficiency. N Engl J Med. 2007;357 (3):266-81.
2. Resnick LM. Calciotropic hormones in salt-sensitive essential hypertension: 1,25-dihydroxyvitamin Dand parathyroid hypertensive factor. J Hypertens Suppl. 1994;12(1):S3-9. (Pubitemid 24082253)
3. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the reninangiotensin system. J Clin Invest. 2002;110(2):229-38. (Pubitemid 34787360)
4. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351(1):33-41.
5. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-53.
6. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-17. (Pubitemid 29407370)
7. Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev. 2008;29(6):726-76.
8. Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab. 2005;288(1):E125-32. (Pubitemid 40023798)
9. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calciumindependent and 1,25(OH)2D3-dependent regulation of the reninangiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int. 2008;74(2):170-9. (Pubitemid 351915078)
10. Yuan W, Pan W, Kong J, Zheng W, Szeto FL, Wong KE, et al. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem. 2007;282(41):29821-30. (Pubitemid 350035242)
11. Li YC, Vitamin D. regulation of the renin-angiotensin system. J Cell Biochem. 2003;88(2):327-31.
12. Resnick LM, Muller FB, Laragh JH. Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann Intern Med. 1986;105(5):649-54. (Pubitemid 17176965)
13. Tomaschitz A, Pilz S, Ritz E, Grammer T, Drechsler C, Boehm BO, März W. Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chim Acta. 2010;411(17-18):1354-60.
14. Vaidya A, Forman JP, Hopkins PN, Seely EW, Williams JS. 25- Hydroxyvitamin D is associated with plasma renin activity and the pressor response to dietary sodium intake in Caucasians. J Renin Angiotensin Aldosterone Syst. 2011;12(3):311-9.
15. Vaidya A, Forman JP, Williams JS. Vitamin D and the vascular sensitivity to angiotensin II in obese Caucasians with hypertension. J Hum Hypertens. 2011;25(11):672-8.
16. Shan J, Resnick LM, Lewanczuk RZ, Karpinski E, Li B, Pang PK. 1,25-dihydroxyvitamin D as a cardiovascular hormone. Effects on calcium current and cytosolic free calcium in vascular smooth muscle cells. Am J Hypertens. 1993;6(12):983-8.
17. Erne P, Bolli P, Burgisser E, Buhler FR. Correlation of platelet calcium with blood pressure. Effect of antihypertensive therapy. N Engl J Med. 1984;310(17):1084-8. (Pubitemid 14131501)
18. Beierwaltes WH. The role of calcium in the regulation of renin secretion. Am J Physiol Renal Physiol. 2010;298(1):F1-F11.
19. Naftilan AJ, Oparil S. The role of calcium in the control of renin release. Hypertension. 1982;4(5):670-5. (Pubitemid 13239684)
20. Bukoski RD, DeWan P, McCarron DA. 1,25 (OH)2 vitamin D3 modifies growth and contractile function of vascular smooth muscle of spontaneously hypertensive rats. Am J Hypertens. 1989;2(7):553-6. (Pubitemid 19184130)
21. Talmor Y, Bernheim J, Klein O, Green J, Rashid G. Calcitriol blunts pro-atherosclerotic parameters through NFkappaB and p38 in vitro. Eur J Clin Invest. 2008;38(8):548-54. (Pubitemid 352019134)
22. Talmor Y, Golan E, Benchetrit S, Bernheim J, Klein O, Green J, et al. Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am J Physiol Renal Physiol. 2008;294(5):F1059-64.
23. WakasugiM, Noguchi T, InoueM, Kazama Y, TawataM, Kanemaru Y, et al. Vitamin D3 stimulates the production of prostacyclin by vascular smooth muscle cells. Prostaglandins. 1991;42(2):127-36.
24. Tarcin O, Yavuz DG, Ozben B, Telli A, Ogunc AV, Yuksel M, et al. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab. 2009;94(10):4023-30.
25. Harris RA, Pedersen-White J, Guo DH, Stallmann-Jorgensen IS, Keeton D, Huang Y, et al. Vitamin D3 supplementation for 16 weeks improves flow-mediated dilation in overweight African- American adults. Am J Hypertens. 2011;24(5):557-62.
26. Jablonski KL, Chonchol M, Pierce GL, Walker AE, Seals DR. 25- Hydroxyvitamin D deficiency is associated with inflammationlinked vascular endothelial dysfunction in middle-aged and older adults. Hypertension. 2011;57(1):63-9.
27. Yiu YF, Chan YH, Yiu KH, Siu CW, Li SW,Wong LY, et al. Vitamin D deficiency is associated with depletion of circulating endothelial progenitor cells and endothelial dysfunction in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):E830-5.
28. Al Mheid I, Patel R, Murrow J, Morris A, Rahman A, Fike L, et al. Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans. J Am Coll Cardiol. 2011;58(2):186-92.
29. Vaidya A, Forman JP, Underwood PC, Hopkins PN, Williams GH, Pojoga LH, et al. The influence of body mass index and reninangiotensin- aldosterone system activity on the relationship between 25-hydroxyvitamin D and adiponectin in Caucasian men. Eur J Endocrinol. 2011;164(6):995-1002.
30. Vaidya A, Pojoga L, Underwood PC, Forman JP, Hopkins PN, Williams GH, Williams JS. The association of plasma resistin with dietary sodium manipulation, the renin-angiotensin-aldosterone system, and 25-hydroxyvitamin D3 in human hypertension. Clin Endocrinol (Oxf). 2011;74(3):294-9.
31. Vaidya A, Williams JS, Forman JP. The independent association between 25-hydroxyvitamin D and adiponectin and its relation with BMI in two large cohorts: the NHS and the HPFS. Obesity (Silver Spring). 2012;20(1):186-91.
32. Thomopoulos C, Daskalaki M, Papazachou O, Rodolakis N, Bratsas A, Papadopoulos DP, et al. Association of resistin and adiponectin with different clinical blood pressure phenotypes. J Hum Hypertens. 2011;25(1):38-46.
33. Yiannikouris F, Gupte M, Putnam K, Cassis L. Adipokines and blood pressure control. Curr Opin Nephrol Hypertens. 2010;19 (2):195-200.
34. Scragg R, SowersM, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens. 2007;20(7):713-9. (Pubitemid 46936167)
35. Hypponen E, Boucher BJ, Berry DJ, Power C. 25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: a cross-sectional study in the 1958 British Birth Cohort. Diabetes. 2008;57(2):298-305.
36. Judd SE, Nanes MS, Ziegler TR, Wilson PW, Tangpricha V. Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr. 2008;87(1):136-41.
37. Hintzpeter B,Mensink GB, ThierfelderW,Muller MJ, Scheidt-Nave C. Vitamin D status and health correlates among German adults. Eur J Clin Nutr. 2008;62(9):1079-89.
38. Burgaz A, Byberg L, Rautiainen S, Orsini N, Hakansson N, Arnlov J, et al. Confirmed hypertension and plasma 25(OH)D concentrations amongst elderly men. J Intern Med. 2011;269 (2):211-8.
39. Reis JP, von Muhlen D, Kritz-Silverstein D, Wingard DL, Barrett- Connor E.Viatamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults. Diabetes Care. 2007;30(6):1549-55. (Pubitemid 46871169)
40. Snijder MB, Lips P, Seidell JC, Visser M, Deeg DJ, Dekker JM, et al. Vitamin D status and parathyroid hormone levels in relation to blood pressure: a population-based study in older men and women. J Intern Med. 2007;261(6):558-65. (Pubitemid 46835978)
41. Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC, et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension. 2007;49 (5):1063-9. (Pubitemid 351664326)
42. Forman JP, Curhan GC, Taylor EN. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension. 2008;52(5):828-32.
43. Griffin FC, Gadegbeku CA, Sowers MR. Vitamin D and subsequent systolic hypertension among women. Am J Hypertens. 2010;24(3):316-21.
44. Jorde R, Figenschau Y, Emaus N, Hutchinson M, Grimnes G. Serum 25-hydroxyvitamin D levels are strongly related to systolic blood pressure but do not predict future hypertension. Hypertension. 2010;55(3):792-8.
45. Rostand SG. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension. 1997;30(2 Pt 1):150-6. (Pubitemid 27328990)
46. Krause R, Buhring M, Hopfenmuller W, Holick MF, Sharma AM. Ultraviolet B and blood pressure. Lancet. 1998;352(9129):709-10. (Pubitemid 28398716)
47. Scragg R, Wishart J, Stewart A, Ofanoa M, Kerse N, Dyall L, et al. No effect of ultraviolet radiation on blood pressure and other cardiovascular risk factors. J Hypertens. 2011;29(9):1749-56.
48. Orwoll ES, Oviatt S. Relationship of mineral metabolism and longterm calcium and cholecalciferol supplementation to blood pressure in normotensive men. Am J Clin Nutr. 1990;52(4):717-21.
49. Pan WH, Wang CY, Li LA, Kao LS, Yeh SH. No significant effect of calcium and vitamin D supplementation on blood pressure and calcium metabolism in elderly Chinese. Chin J Physiol. 1993;36 (2):85-94.
50. Scragg R, Khaw KT, Murphy S. Effect of winter oral vitamin D3 supplementation on cardiovascular risk factors in elderly adults. Eur J Clin Nutr. 1995;49(9):640-6.
51. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab. 2001;86(4):1633-7. (Pubitemid 32377290)
52. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83(4):754-9. (Pubitemid 44713136)
53. Major GC, Alarie F, Dore J, Phouttama S, Tremblay A. Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. Am J Clin Nutr. 2007;85(1):54-9. (Pubitemid 46067615)
54. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD. Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet Med. 2008;25 (3):320-5. (Pubitemid 351322698)
55. Margolis KL, Ray RM, Van Horn L, Manson JE, Allison MA, Black HR, et al. Effect of calcium and vitamin D supplementation on blood pressure: the Women's Health Initiative Randomized Trial. Hypertension. 2008;52(5):847-55.
56. Zittermann A, Frisch S, Berthold HK, Gotting C, Kuhn J, Kleesiek K, et al. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr. 2009;89(5):1321-7.
57. Daly RM, Nowson CA. Long-term effect of calcium-vitamin D(3) fortified milk on blood pressure and serum lipid concentrations in healthy older men. Eur J Clin Nutr. 2009;63(8):993-1000.
58. Jorde R, Figenschau Y. Supplementation with cholecalciferol does not improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D levels. Eur J Nutr. 2009;48(6):349-54.
59. Nagpal J, Pande JN, Bhartia A. A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet Med. 2009;26(1):19-27.
60. Jorde R, Sneve M, Torjesen P, Figenschau Y. No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. J Intern Med. 2010;267(5):462-72.
61. Vaidya A, Forman JP. Vitamin D and hypertension: current evidence and future directions. Hypertension. 2010;56(5):774-9.
62. Cashman KD, Hill TR, Lucey AJ, Taylor N, Seamans KM, Muldowney S, et al. Estimation of the dietary requirement for vitamin D in healthy adults. Am J Clin Nutr. 2008;88(6):1535-42.
63. Cashman KD,Wallace JM, Horigan G, Hill TR, Barnes MS, Lucey AJ, et al. Estimation of the dietary requirement for vitamin D in free-living adults >064 y of age. Am J Clin Nutr. 2009;89 (5):1366-74.
64. Lehtonen-Veromaa M, Mottonen T, Nuotio I, Irjala K, Viikari J. The effect of conventional vitamin D(2) supplementation on serum 25(OH)D concentration is weak among peripubertal Finnish girls: a 3-y prospective study. Eur J Clin Nutr. 2002;56(5):431-7. (Pubitemid 34520851)
65. Witham MD, NadirMA, Struthers AD. Effect of vitamin D on blood pressure: a systematic review and meta-analysis. J Hypertens. 2009;27(10):1948-54.
66. Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K, et al. Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med. 2010;152(5):307-14.
67. Burgaz A, Orsini N, Larsson SC,Wolk A. Blood 25-hydroxyvitamin D concentration and hypertension: a meta-analysis. J Hypertens. 2011;29(4):636-45.
68. Elamin MB, Abu Elnour NO, Elamin KB, FatourechiMM, Alkatib AA, Almandoz JP, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96(7):1931-42.
69. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53-8.
70. Zhang Y, Kong J, Deb DK, Chang A, Li YC. Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. J Am Soc Nephrol. 2010;21(6):966-73.
71. Wang XX, Jiang T, Shen Y, Santamaria H, Solis N, Arbeeny C, et al. Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism. Am J Physiol Renal Physiol. 2011;300(3):F801-10.
72. Deb DK, Sun T, Wong KE, Zhang Z, Ning G, Zhang Y, et al. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int. 2010;77(11):1000-9.
73. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci U S A. 2008;105(41):15896-901.
74. Ohara I, Tanimoto M, Gohda T, Yamazaki T, Hagiwara S, Murakoshi M, et al. Effect of combination therapy with angiotensin receptor blocker and 1,25-Dihydroxyvitamin D3 in Type 2 diabetic nephropathy in KK-Ay/Ta mice. Nephron Exp Nephrol. 2011;117(4):e124-32.
75. Forman JP, Williams JS, Fisher ND. Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension. 2010;55(5):1283-8.
76. Barreto DV, Barreto FC, Liabeuf S, TemmarM, Boitte F, Choukroun G, et al. Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4 (6):1128-35.
77. Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol. 2004;24(5):503-10. (Pubitemid 39656665)
78. de Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 2007;50(1):69-77. (Pubitemid 46962855)
79. Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 2009;75(1):88-95.
80. de Boer IH, Katz R, Chonchol M, Ix JH, Sarnak MJ, Shlipak MG, et al. Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate. Clin J Am Soc Nephrol. 2011;6(9):2141-9.
81. Ureña-Torres P, Metzger M, Haymann JP, Karras A, Boffa JJ, Flamant M, NephroTest Study Group, et al. Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD. Am J Kidney Dis. 2011;58(4):544-53.
82. Kim MJ, Frankel AH, Donaldson M, Darch SJ, Pusey CD, Hill PD. Oral cholecalciferol decreases albuminuria and urinary TGF-?1 in patients with type 2 diabetic nephropathy on established reninangiotensin- aldosterone system inhibition. Kidney Int. 2011;80 (8):851-60.
83. Kandula P, Dobre M, Schold JD, Schreiber Jr. MJ, Mehrotra R, Navaneethan SD. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol. 2011;6(1):50-62.
84. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005;68(6):2823-8. (Pubitemid 43251029)
85. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension. 2008;52(2):249-55.
86. Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PK. Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial. Am J Kidney Dis. 2008;51(5):724-31. (Pubitemid 351626254)
87. Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis. 2009;54(4):647-52.
88. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010;376(9752):1543-51.
89. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349(5):446-56. (Pubitemid 36910023)
90. Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol. 2008;19(8):1613-9.
91. Naves-Diaz M,Alvarez-Hernandez D, Passlick-Deetjen J, Guinsburg A, Marelli C, Rodriguez-Puyol D, et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int. 2008;74(8):1070-8.
92. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, et al. Lower risk for cardiovascular mortality in oral 1alphahydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant. 2004;19(1):179-84. (Pubitemid 38072630)
93. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo Jr. CA, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005;16(4):1115-25. (Pubitemid 41710323)
94. Wolf M, Betancourt J, Chang Y, Shah A, Teng M, Tamez H, et al. Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol. 2008;19(7):1379-88.